Assessment of the humoral immune response to cancer

Journal of Proteomics

Volumn 75, Issue 15, 2012, Pages 4573-4579

  Murphy, Mairead Anne ^a,b   O'Leary, John James ^a   Cahill, Dolores Josephine ^b  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Autoantibody; Cancer; Immunoproteomics; Immunosculpting; Tumour associated antigen

Indexed keywords

AUTOANTIBODY;

ANTIBODY RESPONSE; CANCER EPIDEMIOLOGY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOREGULATION; IMMUNOSELECTION; IMMUNOSUBVERSION; IMMUNOSURVEILLANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, NEOPLASM; ANTIGENS, NEOPLASM; AUTOANTIBODIES; HUMANS; IMMUNITY, HUMORAL; NEOPLASMS;

EID: 84864089353     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2012.01.021     Document Type: Review

References (68)

1. Chaput N., Conforti R., Viaud S., Spatz A., Zitvogel L. The Janus face of dendritic cells in cancer. Oncogene 2008, 27:5920-5931.
2. Whiteside T.L. The tumor microenvironment and its role in promoting tumor growth. Oncogene 2008, 27:5904-5912.
3. Dunn G.P., Bruce A.T., Ikeda H., Old L.J., Schreiber R.D. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002, 3:991-998.
4. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
5. Zitvogel L., Tesniere A., Kroemer G. Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 2006, 6:715-727.
6. Unni A.M., Bondar T., Medzhitov R. Intrinsic sensor of oncogenic transformation induces a signal for innate immunosurveillance. Proc Natl Acad Sci U S A 2008, 105:1686-1691.
7. Wiemann K., Mittrucker H.W., Feger U., Welte S.A., Yokoyama W.M., Spies T., et al. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 2005, 175:720-729.
8. Diefenbach A., Jensen E.R., Jamieson A.M., Raulet D.H. Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 2001, 413:165-171.
9. Waldhauer I., Steinle A. NK cells and cancer immunosurveillance. Oncogene 2008, 27:5932-5943.
10. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 2003, 3:781-790.
11. McGilvray R.W., Eagle R.A., Watson N.F., Al-Attar A., Ball G., Jafferji I., et al. NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 2009, 15:6993-7002.
12. McGilvray R.W., Eagle R.A., Rolland P., Jafferji I., Trowsdale J., Durrant L.G. ULBP2 and RAET1E NKG2D ligands are independent predictors of poor prognosis in ovarian cancer patients. Int J Cancer 2010 Sept 1, 127(6):1412-1420.
13. Guerra N., Tan Y.X., Joncker N.T., Choy A., Gallardo F., Xiong N., et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 2008, 28:571-580.
14. Dunn G.P., Old L.J., Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004, 21:137-148.
15. Reiman J.M., Kmieciak M., Manjili M.H., Knutson K.L. Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol 2007, 17:275-287.
16. Merlo L.M., Pepper J.W., Reid B.J., Maley C.C. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6:924-935.
17. Mellemkjaer L., Hammarstrom L., Andersen V., Yuen J., Heilmann C., Barington T., et al. Cancer risk among patients with IgA deficiency or common variable immunodeficiency and their relatives: a combined Danish and Swedish study. Clin Exp Immunol 2002, 130:495-500.
18. Salavoura K., Kolialexi A., Tsangaris G., Mavrou A. Development of cancer in patients with primary immunodeficiencies. Anticancer Res 2008, 28:1263-1269.
19. Schreiber T.H., Podack E.R. A critical analysis of the tumour immunosurveillance controversy for 3-MCA-induced sarcomas. Br J Cancer 2009, 101:381-386.
20. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410:1107-1111.
21. Kryczek I., Lange A., Mottram P., Alvarez X., et al. CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers. Cancer Res 2005, 65:465-472.
22. Yigit R., Massuger L.F., Figdor C.G., Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010 May, 117(2):366-372.
23. Rodriguez P.C., Ochoa A.C. Arginine regulation by myeloid derived suppressor cells and tolerance in cancer: mechanisms and therapeutic perspectives. Immunol Rev 2008, 222:180-191.
24. Lechner M., Lirk P., Rieder J. Inducible nitric oxide synthase (iNOS) in tumor biology: the two sides of the same coin. Semin Cancer Biol 2005, 15:277-289.
25. Ran Y., Hu H., Zhou Z., Yu L., Sun L., Pan J., et al. Profiling tumor-associated autoantibodies for the detection of colon cancer. Clin Cancer Res 2008, 14:2696-2700.
26. Zhong L., Ge K., Zu J.C., Zhao L.H., Shen W.K., Wang J.F., et al. Autoantibodies as potential biomarkers for breast cancer. Breast Cancer Res 2008, 10:R40.
27. Gnjatic S., Ritter E., Buchler M.W., Giese N.A., Brors B., Frei C., et al. Seromic profiling of ovarian and pancreatic cancer. Proc Natl Acad Sci U S A 2010, 107:5088-5093.
28. Biomarkers Definitions Working Group preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
29. Ait-Tahar K., Damm-Welk C., Burkhardt B., Zimmermann M., Klapper W., Reiter A., et al. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk. Blood 2010, 115:3314-3319.
30. Soussi T., Wiman K.G. Shaping genetic alterations in human cancer: the p53 mutation paradigm. Cancer Cell 2007, 12:303-312.
31. Mor G., Visintin I., Lai Y., Zhao H., Schwartz P., Rutherford T., et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005, 102:7677-7682.
32. Suzuki H., Akakura K., Igarashi T., Ueda T., Ito H., Watanabe M., et al. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters. J Urol 2004, 171:182-186.
33. Tang R., Yeh C.Y., Wang J.Y., Changchien C.R., Chen J.S., Hsieh L.L. Serum p53 antibody as tumor marker for follow-up of colorectal cancer after curative resection. Ann Surg Oncol 2009, 16:2516-2523.
34. Numa F., Umayahara K., Suehiro Y., Hirakawa H., Nawata S., Suminami Y., et al. Serum anti-p53 antibodies in uterine and ovarian cancer: association with DNA sequence copy number abnormalities. Tumour Biol 2001, 22:162-168.
35. Soussi T. p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 2000, 60:1777-1788.
36. Lubin R., Zalcman G., Bouchet L., Tredanel J., Legros Y., Cazals D., et al. Serum p53 antibodies as early markers of lung cancer. Nat Med 1995, 1:701-702.
37. Patwa T.H., Li C., Poisson L.M., Kim H.Y., Pal M., Ghosh D., et al. The identification of phosphoglycerate kinase-1 and histone H4 autoantibodies in pancreatic cancer patient serum using a natural protein microarray. Electrophoresis 2009, 30:2215-2226.
38. Petricoin E.F., Ardekani A.M., Hitt B.A., Levine P.J., Fusaro V.A., Steinberg S.M., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 2002, 359:572-577.
39. Hudson M.E., Pozdnyakova I., Haines K., Mor G., Snyder M. Identification of differentially expressed proteins in ovarian cancer using high-density protein microarrays. Proc Natl Acad Sci U S A 2007, 104:17494-17499.
40. Shimada H., Nakashima K., Ochiai T., Nabeya Y., Takiguchi M., Nomura F., et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol 2005, 26:77-86.
41. Mintz P.J., Kim J., Do K.A., Wang X., Zinner R.G., Cristofanilli M., et al. Fingerprinting the circulating repertoire of antibodies from cancer patients. Nat Biotechnol 2003, 21:57-63.
42. Anderson K.S., LaBaer J. The sentinel within: exploiting the immune system for cancer biomarkers. J Proteome Res 2005, 4:1123-1133.
43. Tan H.T., Low J., Lim S.G., Chung M.C. Serum autoantibodies as biomarkers for early cancer detection. FEBS J 2009, 276:6880-6904.
44. Hanash S. Harnessing immunity for cancer marker discovery. Nat Biotechnol 2003, 21:37-38.
45. Prince S., Zeidman A., Dekel Y., Ram E., Koren R. Expression of epithelial cell adhesion molecule in gallbladder carcinoma and its correlation with clinicopathologic variables. Am J Clin Pathol 2008, 129:424-429.
46. Kim J.H., Herlyn D., Wong K.K., Park D.C., Schorge J.O., Lu K.H., et al. Identification of epithelial cell adhesion molecule autoantibody in patients with ovarian cancer. Clin Cancer Res 2003, 9:4782-4791.
47. Wenqi D., Li W., Shanshan C., Bei C., Yafei Z., Feihu B., et al. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J Cancer Res Clin Oncol 2009, 135:1277-1285.
48. Liu G., Atteridge C.L., Wang X., Lundgren A.D., Wu J.D. The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J Immunol 2010, 184:3346-3350.
49. Waldhauer I., Goehlsdorf D., Gieseke F., Weinschenk T., Wittenbrink M., Ludwig A., et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008, 68:6368-6376.
50. Lucas N., Day M.L. The role of the disintegrin metalloproteinase ADAM15 in prostate cancer progression. J Cell Biochem 2009, 106:967-974.
51. Carl-McGrath S., Lendeckel U., Ebert M., Roessner A., Rocken C. The disintegrin-metalloproteinases ADAM9, ADAM12, and ADAM15 are upregulated in gastric cancer. Int J Oncol 2005, 26:17-24.
52. Ko S.Y., Lin S.C., Wong Y.K., Liu C.J., Chang K.W., Liu T.Y. Increase of disintergin metalloprotease 10 (ADAM10) expression in oral squamous cell carcinoma. Cancer Lett 2007, 245:33-43.
53. Fujita J., Takeuchi T., Dobashi N., Ohtsuki Y., Tokuda M., Takahara J. Detection of anti-ADAM 10 antibody in serum of a patient with pulmonary fibrosis associated with dermatomyositis. Ann Rheum Dis 1999, 58:770-772.
54. Park J., Kim D.S., Shim T.S., Lim C.M., Koh Y., Lee S.D., et al. Lung cancer in patients with idiopathic pulmonary fibrosis. Eur Respir J 2001, 17:1216-1219.
55. Stockton D., Doherty V.R., Brewster D.H. Risk of cancer in patients with dermatomyositis or polymyositis, and follow-up implications: a Scottish population-based cohort study. Br J Cancer 2001, 85:41-45.
56. Anderson K.S., Ramachandran N., Wong J., Raphael J.V., Hainsworth E., Demirkan G., et al. Application of protein microarrays for multiplexed detection of antibodies to tumor antigens in breast cancer. J Proteome Res 2008, 7:1490-1499.
57. Gagnon A., Kim J.H., Schorge J.O., Ye B., Liu B., Hasselblatt K., et al. Use of a combination of approaches to identify and validate relevant tumor-associated antigens and their corresponding autoantibodies in ovarian cancer patients. Clin Cancer Res 2008, 14:764-771.
58. Taylor B.S., Pal M., Yu J., Laxman B., Kalyana-Sundaram S., Zhao R., et al. Humoral response profiling reveals pathways to prostate cancer progression. Mol Cell Proteomics 2008, 7:600-611.
59. Hahn W.C., Weinberg R.A. Modelling the molecular circuitry of cancer. Nat Rev Cancer 2002, 2:331-341.
60. Bellone M., Ceccon M., Grioni M., Jachetti E., Calcinotto A., Napolitano A., et al. iNKT cells control mouse spontaneous carcinoma independently of tumor-specific cytotoxic T cells. PLoS One 2010, 5:e8646.
61. Riond J., Rodriguez S., Nicolau M.L., al Saati T., Gairin J.E. In vivo major histocompatibility complex class I (MHCI) expression on MHCIlow tumor cells is regulated by gammadelta T and NK cells during the early steps of tumor growth. Cancer Immun 2009, 9:10.
62. Rosenberg S.A., Yang J.C., Restifo N.P. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
63. Huang B., Zhao J., Unkeless J.C., Feng Z.H., Xiong H. TLR signaling by tumor and immune cells: a double-edged sword. Oncogene 2008, 27:218-224.
64. Ashiru O., Boutet P., Fernandez-Messina L., Aguera-Gonzalez S., Skepper J.N., Valés-Gómez M., et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA*008 that is shed by tumor cells in exosomes. Cancer Res 2010, 70:481-489.
65. Toubi E., Shoenfeld Y. Protective autoimmunity in cancer (review). Oncol Rep 2007, 17:245-251.
66. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
67. Koebel C.M., Vermi W., Swann J.B., Zerafa N., Rodig S.J., Old L.J., et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007, 450:903-907.
68. Melief C.J. Cancer: immune pact with the enemy. Nature 2007, 450:803-804.